MedTrace Logo

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

NCT01357655 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2017-03-14

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to compare response rates in newly diagnosed Chronic Phase (CP) CML subjects treated with dasatinib plus BMS-833923 versus dasatinib alone.

Conditions

Interventions

DRUG

Dasatinib

Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response

DRUG

BMS-833923

Capsules, Oral, dose to be determined, Once daily, approximately 2 years depending on response

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • United States
  • Argentina
  • Belgium
  • Canada
  • Finland
  • France
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01357655 on ClinicalTrials.gov